In a report published Thursday, MLV & Co. analyst Arlinda Lee initiated coverage on Sorrento Therapeutics SRNE with a Buy rating and $9.00 price target.
In the report, MLV & Co. noted, “We are initiating coverage of SRNE with a Buy rating and $9 price target. We believe that lead product candidate Cynviloq, a next generation paclitaxel, has a 75% chance of showing bioequivalence to CELG's Abraxane (CELG – $-159.94 - not covered), gaining FDA approval, and capturing 25% of the addressable paclitaxel market. Second product candidate resiniferatoxin (RTX), a non-opioid severe pain drug, also contributes to our probability-adjusted valuation.”
Sorrento Therapeutics closed on Wednesday at $5.62.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in